Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.
Montes-Moreno S, Batlle A, de Villambrosía SG, Sánchez-Espiridión B, Cereceda L, González-Barca E, Purroy N, Pardal E, Martín A, Grande C, Mazorra F, Insunza A, Quero C, Aguiar D, Cruz MA, Rueda A, Llanos M, Codina JG, Arroyo FR, Caballero D, Conde E, López A, Provencio M, Piris M.
Montes-Moreno S, et al. Among authors: caballero d.
Haematologica. 2014 Aug;99(8):e138-41. doi: 10.3324/haematol.2014.104976. Epub 2014 Apr 24.
Haematologica. 2014.
PMID: 24763400
Free PMC article.
Clinical Trial.
No abstract available.